Shubham Pant: Data from the Phase 1 AMPLIFY-201 trial of the ELI-002 KRAS vaccine at the ESMO-IO Conference
Shubham Pant , Professor of Gastrointestinal Medical Oncology and Investigational Cancer Therapeutics at MD Anderson Cancer Center, shared on LinkedIn:
“I’m honored to have had the opportunity to present updated data from the Phase 1 AMPLIFY-201 trial of the ELI-002 KRAS vaccine at the ESMO – European Society for Medical Oncology-IO Conference in Geneva.
Our presentation highlighted longer-term survival data, building on the initial results published in Nature Medicine.
Key findings included:
– 25 patients enrolled (20 PDAC, 5 CRC)
– Patients with KRAS G12D and G12R mutations, no evidence of disease but high relapse risk after resection
– 84% of patients showed biomarker declines (ctDNA, CA 19-9, CEA)
– Median follow-up: 19.7 months | Median RFS: 16.33 months (not reached for patients with ≥ median T-cell response)
Enrollment for the randomized Phase 2 trial is now complete — 135 patients enrolled in just 10 months!
Looking forward to the next phase of Cracking KRAS.”
Authors: Shubham Pant, Zev A. Wainberg, Colin D. Weekes, Muhammad Furqan, Pashtoon M. Kasi, Craig E. Devoe, Alexis D. Leal, Vincent Chung, Olca Basturk, Haley VanWyk, Amy M. Tavares, Lochana M. Seenappa, James R. Perry, Thian Kheoh, Lisa K. McNeil, Esther Welkowsky, Peter C. DeMuth, Christopher M. Haqq, Eileen M. O’Reilly
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023